Cold Agglutinin Disease Therapies
Cold Agglutinin Disease Market


Cold Agglutinin Disease 


Cold Agglutinin Disease (CAD) is an uncommon autoimmune hemolytic anemia in which a well-defined, clonal low-grade lymphoproliferative disorder of the bone marrow results in erythrocyte destruction mediated by the classical complement pathway. It is mediated by cold agglutinins (CA), without any underlying disease such as aggressive lymphoma, other overt malignancies, or specific infections.


Cold Agglutinin Disease Epidemiology Segmentation in the 7MM 


  • Total Prevalent Cases of Cold Agglutinin Disease
  • Total Diagnosed Cases of Cold Agglutinin Disease
  • Total Gender-specific Cases of Cold Agglutinin Disease
  • Total Type-specific Cases of Cold Agglutinin Disease
  • Total Treated Cases of Cold Agglutinin Disease


Cold Agglutinin Disease Epidemiological Insights Observed in the 7MM (2021)


  • The total prevalent cases of Cold Agglutinin Disease in the 7MM were found to be 12.8k.
  • The total diagnosed cases of Cold Agglutinin Disease in the US was estimated to be 5.4k.
  • The total treated cases of Cold Agglutinin Disease in Japan were found to be 2.0k.


Cold Agglutinin Disease Market Insight


The market size of Cold Agglutinin Disease in the 7MM was found to be USD 60.9 million in 2021.  


Cold Agglutinin Disease Market Drivers


  • Less competitive scenario
  • Novel mechanism of action
  • Perks related to rare diseases


Cold Agglutinin Disease Market Barriers


  • Lack of robust developmental pipeline
  • Limitations related to complement inhibitors
  • Limitations of B-cell-directed therapies


Cold Agglutinin Disease Emerging Therapies


The emerging drugs in the Cold Agglutinin Disease market are

  • BIVV009
  • Aspaveli
  • Empaveli
  • LNP023
  • INCB050465
  • BIVV020, and many others


Cold Agglutinin Disease Key Players 


The key players working in the Cold Agglutinin Disease market are


  • Sanofi
  • Bioverativ
  • Sobi
  • Apellis Pharmaceuticals
  • Novartis
  • Incyte Corporation, and others